王宏波 1,2 , 徐珞 1
  • 1.青島大學(xué)醫(yī)學(xué)院病理生理教研室(山東青島 266021);;
  • 2.墨市人民醫(yī)院胃腸外科(山東即墨 266200);

目的檢測(cè)胃動(dòng)素在胃癌組織中的表達(dá)并探討其與胃癌臨床病理特征的關(guān)系。方法采用免疫組化SP法檢測(cè)胃癌、癌旁及正常胃黏膜組織中胃動(dòng)素蛋白的表達(dá)，對(duì)胃癌組織中胃動(dòng)素蛋白的表達(dá)及其與胃癌臨床病理特征之間的關(guān)系進(jìn)行分析。結(jié)果胃癌組織中胃動(dòng)素蛋白表達(dá)水平(1 206.43±631.67)明顯高于正常胃黏膜組織(890.55±98.67)和癌旁組織(922.75±265.99)，P lt;0.01，而癌旁組織和正常胃黏膜組織中胃動(dòng)素蛋白表達(dá)水平的差異無統(tǒng)計(jì)學(xué)意義(P gt;0.05)。胃動(dòng)素蛋白表達(dá)與腫瘤部位、腫瘤分化程度及淋巴結(jié)轉(zhuǎn)移有關(guān)(P lt;0.05)。結(jié)論胃動(dòng)素可能參與胃癌的發(fā)生，并與胃癌的侵襲和轉(zhuǎn)移相關(guān)。

引用本文： 王宏波,徐珞. 胃動(dòng)素在胃癌組織中的表達(dá)及其意義. 中國(guó)普外基礎(chǔ)與臨床雜志, 2011, 18(2): 183-186. doi: 復(fù)制

1. Cunningham SC, Kamangar F, Kim MP, et al. Claudin4, mitogenactivated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions [J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(2): 281287.
2. Konturek PC, Kania J, Konturek JW, et al. H. pylori infection, atrophic gastritis, cytokines, gastrin, COX2, PPAR γ and impaired apoptosis in gastric carcinogenesis [J]. Med Sci Monit, 2003, 9(7): SR53SR66.
3. Hu C, Yi C, Hao Z, et al. The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells [J]. Cancer Biol Ther, 2004, 3(8): 726730.
4. Matsubara J, Yamada Y, Nakajima TE, et al. Clinical significance of insulinlike growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer [J]. Oncology, 2008, 74(12): 7683.
5. Ito M, Tanaka S, Maeda M, et al. Role of the gastringastrin receptor system in the expansive growth of human gastric neoplasms [J]. Digestion, 2008, 78(23): 163170.
6. 葉序卷, 王立. 胃癌與相關(guān)胃腸激素的關(guān)系研究進(jìn)展 [J]. 國(guó)際消化病雜志, 2006, 26(4): 253256.
7. Maev IV, Mel’nikova EV, Kashin SV, et al. Serologic screening for preneoplastic pathology and early stomach cancer [J]. Klin Med (Mosk), 2008, 86(11): 4348.
8. Kamerling IM, Van Haarst AD, Burggraaf J, et al. Motilin effects on the proximal stomach in patients with functional dyspepsia and healthy volunteers [J]. Am J Physiol Gastrointest Liver Physiol, 2003, 284(5): G776G781.
9. Sanger GJ. Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases [J]. Drug Discov Today, 2008, 13(56): 234239.
10. Pendleton H, Ekman R, Olsson R, et al. Motilin concentrations in relation to gastro intestinal dysmotility in diabetes mellitus [J]. Eur J Intern Med, 2009, 20(6): 654659.
11. National Comprehensive Cancer Network. NCCN胃癌臨床實(shí)踐指南（中國(guó)版）專家組. 胃癌臨床實(shí)踐指南(中國(guó)版) [S]. 2009： 20.
12. Itoh Z. Motilin and clinical application [J]. Peptides, 1997, 18(4): 593608.
13. Xu L, Depoortere I, Tang M, et al. Identification and expression of the motilin precursor in the guinea pig [J]. FEBS Lett, 2001, 490(12): 710.
14. Xu L, Depoortere I, Tomasetto C, et al. Evidence for the presence of motilin, ghrelin, and the motilin and ghrelin receptor in neurons of the myenteric plexus [J]. Regul Pept, 2005, 124(13): 119125.
15. Takeshita E, Matsuura B, Dong M, et al. Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract [J]. J Gastroenterol, 2006, 41(3): 223230.
16. Ter Beek WP, Muller ES, van den Berg M, et al. Motilin receptor expression in smooth muscle, myenteric plexus, and mucosa of human inflamed and noninflamed intestine [J]. Inflamm Bowel Dis, 2008, 14(5): 612619.
17. Ozaki K, Yogo K, Sudo H, et al. Effects of mitemcinal (GM611), an acidresistant nonpeptide motilin receptor agonist on the gastrointestinal contractile activity in conscious dogs [J]. Pharmacology, 2007, 79(4): 223235.
18. McCallum RW, Cynshi O. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesisa randomized, multicentre, placebocontrolled study [J]. Aliment Pharmacol Ther, 2007, 26(8): 11211130.
19. De Smet B, Mitselos A, Depoortere I. Motilin and ghrelin as prokinetic drug targets [J]. Pharmacol Ther, 2009, 123(2): 207223.
20. Trudel L, Tomasetto C, Rio MC, et al. Ghrelin/motilinrelated peptide is a potent prokinetic to reverse gastric postoperative ileus in rat [J]. Am J Physiol Gastrointest Liver Physiol, 2002, 282(6): G948G952.
21. 鄧鋼明, 袁慶豐. 胃癌患者血漿胃動(dòng)素與胃收縮運(yùn)動(dòng)的關(guān)系探討 [J]. 蚌埠醫(yī)學(xué)院學(xué)報(bào), 2001, 26(3): 245.
22. 龍憲和. 胃腸肝等癌癥患者血漿胃動(dòng)素觀察的臨床意義 [J]. 標(biāo)記免疫分析與臨床, 2003, 10(3): 181182.
23. 呂賓, 葉再元, 朱林喜, 等．胃癌組織及癌區(qū)動(dòng)、靜脈血胃腸激素的研究 [J]. 世界華人消化雜志, 2000, 8(12): 14291430.
24. 楊小慧, 劉勇剛, 陳海鷹, 等. 消化道腫瘤患者化療前后血漿胃動(dòng)素和降鈣素基因相關(guān)肽的變化 [J]. 中國(guó)基層醫(yī)藥, 2008, 15(1): 2021.
25. 劉建平. 化濁解毒湯對(duì)慢性萎縮性胃炎大鼠MTL、SS、ET的影響 [D]. 河北: 河北醫(yī)科大學(xué), 2009: 2639.
  1. 1. Cunningham SC, Kamangar F, Kim MP, et al. Claudin4, mitogenactivated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions [J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(2): 281287.
  2. 2. Konturek PC, Kania J, Konturek JW, et al. H. pylori infection, atrophic gastritis, cytokines, gastrin, COX2, PPAR γ and impaired apoptosis in gastric carcinogenesis [J]. Med Sci Monit, 2003, 9(7): SR53SR66.
  3. 3. Hu C, Yi C, Hao Z, et al. The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells [J]. Cancer Biol Ther, 2004, 3(8): 726730.
  4. 4. Matsubara J, Yamada Y, Nakajima TE, et al. Clinical significance of insulinlike growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer [J]. Oncology, 2008, 74(12): 7683.
  5. 5. Ito M, Tanaka S, Maeda M, et al. Role of the gastringastrin receptor system in the expansive growth of human gastric neoplasms [J]. Digestion, 2008, 78(23): 163170.
  6. 6. 葉序卷, 王立. 胃癌與相關(guān)胃腸激素的關(guān)系研究進(jìn)展 [J]. 國(guó)際消化病雜志, 2006, 26(4): 253256.
  7. 7. Maev IV, Mel’nikova EV, Kashin SV, et al. Serologic screening for preneoplastic pathology and early stomach cancer [J]. Klin Med (Mosk), 2008, 86(11): 4348.
  8. 8. Kamerling IM, Van Haarst AD, Burggraaf J, et al. Motilin effects on the proximal stomach in patients with functional dyspepsia and healthy volunteers [J]. Am J Physiol Gastrointest Liver Physiol, 2003, 284(5): G776G781.
  9. 9. Sanger GJ. Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases [J]. Drug Discov Today, 2008, 13(56): 234239.
  10. 10. Pendleton H, Ekman R, Olsson R, et al. Motilin concentrations in relation to gastro intestinal dysmotility in diabetes mellitus [J]. Eur J Intern Med, 2009, 20(6): 654659.
  11. 11. National Comprehensive Cancer Network. NCCN胃癌臨床實(shí)踐指南（中國(guó)版）專家組. 胃癌臨床實(shí)踐指南(中國(guó)版) [S]. 2009： 20.
  12. 12. Itoh Z. Motilin and clinical application [J]. Peptides, 1997, 18(4): 593608.
  13. 13. Xu L, Depoortere I, Tang M, et al. Identification and expression of the motilin precursor in the guinea pig [J]. FEBS Lett, 2001, 490(12): 710.
  14. 14. Xu L, Depoortere I, Tomasetto C, et al. Evidence for the presence of motilin, ghrelin, and the motilin and ghrelin receptor in neurons of the myenteric plexus [J]. Regul Pept, 2005, 124(13): 119125.
  15. 15. Takeshita E, Matsuura B, Dong M, et al. Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract [J]. J Gastroenterol, 2006, 41(3): 223230.
  16. 16. Ter Beek WP, Muller ES, van den Berg M, et al. Motilin receptor expression in smooth muscle, myenteric plexus, and mucosa of human inflamed and noninflamed intestine [J]. Inflamm Bowel Dis, 2008, 14(5): 612619.
  17. 17. Ozaki K, Yogo K, Sudo H, et al. Effects of mitemcinal (GM611), an acidresistant nonpeptide motilin receptor agonist on the gastrointestinal contractile activity in conscious dogs [J]. Pharmacology, 2007, 79(4): 223235.
  18. 18. McCallum RW, Cynshi O. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesisa randomized, multicentre, placebocontrolled study [J]. Aliment Pharmacol Ther, 2007, 26(8): 11211130.
  19. 19. De Smet B, Mitselos A, Depoortere I. Motilin and ghrelin as prokinetic drug targets [J]. Pharmacol Ther, 2009, 123(2): 207223.
  20. 20. Trudel L, Tomasetto C, Rio MC, et al. Ghrelin/motilinrelated peptide is a potent prokinetic to reverse gastric postoperative ileus in rat [J]. Am J Physiol Gastrointest Liver Physiol, 2002, 282(6): G948G952.
  21. 21. 鄧鋼明, 袁慶豐. 胃癌患者血漿胃動(dòng)素與胃收縮運(yùn)動(dòng)的關(guān)系探討 [J]. 蚌埠醫(yī)學(xué)院學(xué)報(bào), 2001, 26(3): 245.
  22. 22. 龍憲和. 胃腸肝等癌癥患者血漿胃動(dòng)素觀察的臨床意義 [J]. 標(biāo)記免疫分析與臨床, 2003, 10(3): 181182.
  23. 23. 呂賓, 葉再元, 朱林喜, 等．胃癌組織及癌區(qū)動(dòng)、靜脈血胃腸激素的研究 [J]. 世界華人消化雜志, 2000, 8(12): 14291430.
  24. 24. 楊小慧, 劉勇剛, 陳海鷹, 等. 消化道腫瘤患者化療前后血漿胃動(dòng)素和降鈣素基因相關(guān)肽的變化 [J]. 中國(guó)基層醫(yī)藥, 2008, 15(1): 2021.
  25. 25. 劉建平. 化濁解毒湯對(duì)慢性萎縮性胃炎大鼠MTL、SS、ET的影響 [D]. 河北: 河北醫(yī)科大學(xué), 2009: 2639.